Technology Development Through Joint Research with Universities and Research Institutions
First written in FY2021. 9 of 15 entries say "Restated". Latest entry: 2026-08-06.
26 other companies' latest entry also says "Advanced".
- 2026-08-06AdvancedEarnings
「In addition, in joint research with the Department of Ophthalmology, School of Medicine, International University of Health and Welfare, and Eiwakai Medical Corporation, we have begun animal studies to evaluate efficacy against corneal epithelial disorders with a view to developing new treatments for eye diseases using conditioned medium derived from umbilical cord mesenchymal cells.」
The new joint research on treatments for eye diseases has progressed to the stage of starting animal studies. - FY2026AdvancedAnnual report
「In December 2025, we also entered into a joint research agreement with the Department of Ophthalmology, School of Medicine, International University of Health and Welfare, and Eiwakai Medical Corporation to develop new treatments for eye diseases using conditioned medium derived from umbilical cord mesenchymal cells.」
In addition to its existing joint research with the University of Tokyo, Osaka University and Osaka Metropolitan University, the company entered into a new joint research agreement targeting treatments for eye diseases. - FY2025RestatedAnnual report
「The main breakdown was ¥5.454 million for joint research on musculoskeletal sports biomechanics with Osaka University; ¥3.621 million for joint research on umbilical cord-derived mesenchymal cells with the Institute of Medical Science, the University of Tokyo, and for the development of treatments using umbilical cords for congenital diseases such as pediatric morphological abnormalities with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital; and ¥8.996 million for research on umbilical cord blood and umbilical cord-derived mesenchymal cell therapies with the University Hospital, Osaka Metropolitan University, among other projects.」
The company continues joint research with Osaka University, the University of Tokyo, Osaka Metropolitan University and others. A breakdown of research expenses was provided, but no new completion or milestone achievement was reported. - FY2024-Q3RestatedAnnual report
「Regarding research and development using umbilical cords, we are promoting the development of a new meniscus treatment through the Course of Sports Biomechanics of the Musculoskeletal System, established with the Department of Sports Medicine, Graduate School of Medicine, Osaka University. We are also continuing to promote the development of treatments for congenital diseases such as pediatric morphological abnormalities with the Cell Processing and Transfusion Division of the Institute of Medical Science, the University of Tokyo and the Tissue Engineering Division of the University of Tokyo Hospital.」
The company continues to develop a meniscus treatment through the course with Osaka University and treatments for congenital diseases with the University of Tokyo. No new completion or milestone achievement was reported. - FY2024-Q2RestatedAnnual report
「Regarding research and development using umbilical cords, we are promoting the development of a new meniscus treatment through the Course of Sports Biomechanics of the Musculoskeletal System, established with the Department of Sports Medicine, Graduate School of Medicine, Osaka University. We are also continuing to promote the development of treatments for congenital diseases such as pediatric morphological abnormalities with the Cell Processing and Transfusion Division of the Institute of Medical Science, the University of Tokyo and the Tissue Engineering Division of the University of Tokyo Hospital.」
The company continues to develop a meniscus treatment through the course with Osaka University and treatments for congenital diseases with the University of Tokyo. No new completion or milestone achievement was reported. - FY2024-Q1RestatedAnnual report
「Regarding research and development using umbilical cords, we are promoting the development of a new meniscus treatment through the Course of Sports Biomechanics of the Musculoskeletal System, established with the Department of Sports Medicine, Graduate School of Medicine, Osaka University. We are also continuing to promote the development of treatments for congenital diseases such as pediatric morphological abnormalities with the Cell Processing and Transfusion Division of the Institute of Medical Science, the University of Tokyo and the Tissue Engineering Division of the University of Tokyo Hospital.」
The company continues to promote the development of a meniscus treatment through the course with Osaka University and the development of treatments for congenital diseases with the University of Tokyo. No new completion or milestone achievement was reported. - FY2023RestatedAnnual report
「Regarding research and development using umbilical cords, we are promoting the development of a new meniscus treatment through the Course of Sports Biomechanics of the Musculoskeletal System, established with the Department of Sports Medicine, Graduate School of Medicine, Osaka University. We are also continuing to promote the development of treatments for congenital diseases such as pediatric morphological abnormalities with the Cell Processing and Transfusion Division of the Institute of Medical Science, the University of Tokyo and the Tissue Engineering Division of the University of Tokyo Hospital.」
The company continues joint research with universities and research institutions, including the course with Osaka University and the development of treatments for congenital diseases with the University of Tokyo. - FY2023-Q2AdvancedAnnual report
「During the current fiscal year, we established the Course of Sports Biomechanics of the Musculoskeletal System with the Department of Sports Medicine, Graduate School of Medicine, Osaka University, and are promoting the development of a new meniscus treatment. We are also promoting the development of treatments for congenital diseases such as pediatric morphological abnormalities with the Cell Processing and Transfusion Division of the Institute of Medical Science, the University of Tokyo and the Tissue Engineering Division of the University of Tokyo Hospital.」
The company established a course with the Department of Sports Medicine, Graduate School of Medicine, Osaka University, and is promoting the development of a new meniscus treatment. It also continues to develop treatments for congenital diseases with the University of Tokyo. - FY2023-Q1RestatedAnnual report
「We continue to focus on joint research with academia in regenerative medicine, including the development of treatments using umbilical cords for congenital diseases such as pediatric morphological abnormalities with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital, and the development of a new meniscus treatment using umbilical cords with the Graduate School of Medicine, Osaka University.」
The company continues to focus on joint research with academia, including the development of treatments using umbilical cords with the University of Tokyo, Osaka University and others. - FY2022RestatedAnnual report
「We continue to focus on joint research with academia in regenerative medicine, including the development of treatments using umbilical cords for congenital diseases such as pediatric morphological abnormalities with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital, and the development of a new meniscus treatment using umbilical cords with the Graduate School of Medicine, Osaka University.」
The company continues to develop treatments using umbilical cords with the University of Tokyo, Osaka University and others, and to conduct joint research with academia. Research and development expenses included ¥7.110 million for the University of Tokyo and others, ¥1.545 million for Osaka Metropolitan University, and ¥909 thousand for Nihon University. - FY2022-Q2RestatedAnnual report
「We continue to focus on joint research with academia in regenerative medicine, including the development of treatments using umbilical cords for congenital diseases such as pediatric morphological abnormalities with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital, and the development of a new meniscus treatment using umbilical cords with the Graduate School of Medicine, Osaka University.」
The company continues joint research with academia, including the development of treatments using umbilical cords with the University of Tokyo, Osaka University and others. - FY2022-Q1RestatedAnnual report
「We have also focused on joint research with academia in regenerative medicine, including the development of treatments using umbilical cords for congenital diseases such as pediatric morphological abnormalities with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital, and the development of a new meniscus treatment using umbilical cords with the Graduate School of Medicine, Osaka University.」
The company continues to focus on developing treatments using umbilical cords and conducting joint research with the University of Tokyo, Osaka University and others. - FY2021First statedAnnual report
「In September 2020, the company entered into joint research agreements with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital concerning the development of technologies for the clinical application of cells derived from perinatal tissues and the establishment of a banking system, and research and development into tissue engineering using autologous umbilical cord-derived cells.」
The company is advancing the clinical application and introduction of cell technologies through joint research and research assistance with the University of Tokyo, Osaka University and Keio University, among others.